<abstract xmlns="http://www.w3.org/1999/xhtml">

<p><bold>Background:</bold> BNT162b2 is a widely used mRNA COVID-19 vaccine for which 8.2% of participants above the age of 56 years have reported diarrhea as an adverse event. This case report highlights the possibility of eosinophilic colitis in post-vaccination diarrhea.</p>
<p><bold>Case report:</bold> A 72-year-old male patient presented with generalized colicky abdominal pain and acute diarrhea after receiving the first dose of the BNT162b2 vaccine. Laboratory examination revealed peripheral blood eosinophilia with cecal and ascending colon mucosal eosinophilia with 100–130 cells/HPF and eosinophilic cryptitis. The patient’s symptoms and eosinophilia resolved spontaneously and did not recur after the second dose of vaccination. More research is needed to confirm eosinophilic colitis as a possible vaccine adverse reaction.</p>
</abstract>

Background: BNT162b2 is a widely used mRNA COVID-19 vaccine for which 8.2% of participants above the age of 56 years have reported diarrhea as an adverse event. This case report highlights the possibility of eosinophilic colitis in post-vaccination diarrhea.
Case report: A 72-year-old male patient presented with generalized colicky abdominal pain and acute diarrhea after receiving the first dose of the BNT162b2 vaccine. Laboratory examination revealed peripheral blood eosinophilia with cecal and ascending colon mucosal eosinophilia with 100–130 cells/HPF and eosinophilic cryptitis. The patient’s symptoms and eosinophilia resolved spontaneously and did not recur after the second dose of vaccination. More research is needed to confirm eosinophilic colitis as a possible vaccine adverse reaction.

A Case of Eosinophilic Colitis after BNT162b2 mRNA COVID-19 Vaccination

Division of Gastroenterology and Hepatology, Department of Medicine

GI Function & Motility Unit, Department of Medicine

Journal of Interdisciplinary Medicine

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

{"article-title":"A Case of Eosinophilic Colitis after BNT162b2 mRNA COVID-19 Vaccination"}

Background: BNT162b2 is a widely used mRNA COVID-19 vaccine for which 8.2% of participants above the age of 56 years have reported diarrhea as an adverse...

A Case of Eosinophilic Colitis after BNT162b2 mRNA COVID-19 Vaccination

Data publikacji: 21 wrz 2022

Zakres stron: 44 - 46

Otrzymano: 20 maj 2022

Przyjęty: 27 cze 2022

DOI: https://doi.org/10.2478/jim-2022-0009

Słowa kluczowe
COVID-19 vaccine, eosinophilic colitis, vaccine adverse reactions

© 2022 Selva Yuwaraj Vadioaloo et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

A Case of Eosinophilic Colitis after BNT162b2 mRNA COVID-19 Vaccination

Data publikacji: 21 wrz 2022

Zakres stron: 44 - 46

Otrzymano: 20 maj 2022

Przyjęty: 27 cze 2022

DOI: https://doi.org/10.2478/jim-2022-0009

Słowa kluczoweCOVID-19 vaccine, eosinophilic colitis, vaccine adverse reactions

© 2022 Selva Yuwaraj Vadioaloo et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Słowa kluczowe
COVID-19 vaccine, eosinophilic colitis, vaccine adverse reactions